
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
Find links to pertinent regulatory and standard setting resources, guidance documents, and guidelines.
over 5 years ago
It Takes a Bio/Pharma Villageover 5 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 5 years ago
Can FDA Reinvent Inspections?over 5 years ago
Growing Pipeline of Antisense Oligonucleotides Prompts Guidanceover 5 years ago
Gene Therapies Target Neurodegenerative Diseasesover 5 years ago
A Real-World Approach to Evaluating Cleanroom Garmentsover 5 years ago
FDA 2021 Guidance Agenda Sees Focus on Generics





